YZYong Zhang

Yong Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yong Zhang has a total of 104 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Sarcoma-Derived Extracellular Vesicles: From Biology to Clinical Translation

    by Qi Zhang, Priya Dhawale, Patricia Sarchet, Hanxing Tong, Ali F. Usmani, Premanshu K. Singh, Shaurya Prakash, Yong Zhang, Raphael E. Pollock, Federica Calore

    Sarcomas constitute a heterogeneous group of rare mesenchymal malignancies encompassing soft tissue and bone sarcomas, whose histological and molecular diversity poses substantial challenges for early diagnosis, disease surveillance, and clinical management. Extracellular vesicles (EVs) are membrane-bound particles that mediate intercellular communication via delivery of bioactive cargo including proteins, nucleic acids, and lipids, and have emerged as promising analytes for minimally invasive liquid biopsy. While the biological functions and clinical value of EVs have been extensively characterized in common epithelial cancers, investigations focusing on sarcoma-derived EVs remain relatively limited and unevenly distributed across histological subtypes. Emerging evidence suggests that EV cargo can reflect molecular features of different sarcoma subtypes, including gene amplifications, fusion transcripts, miRNAs, lncRNAs, and tumor-associated proteins. This review provides an overview of current advances in sarcoma-derived EV research. We outline the classification of EV subtypes and their molecular cargo characteristics, with emphasis on features particularly relevant to sarcoma biology and biomarker development, as well as the technical principles, advantages, and limitations of EV isolation methodologies. We then focus on the roles of sarcoma-derived EVs in mediating tumor-host crosstalk, including facilitating the establishment of the pre-metastatic niche, promoting immunosuppression and immune evasion, and remodeling the tumor microenvironment. We further summarize emerging translational applications of sarcoma-derived EVs, covering their utility as circulating biomarkers for disease diagnosis, longitudinal monitoring, and treatment response assessment, as well as their potential as therapeutic targets for anti-tumor intervention. Where direct evidence in sarcoma remains limited, we distinguish findings established in sarcoma models from mechanisms extrapolated from other malignancies. Finally, we discuss current challenges to clinical translation, including small patient cohorts, lack of standardized technical protocols, and underrepresentation of rare histological subtypes. We propose that standardized EV isolation and characterization methods, larger collaborative datasets, and integration of multimodal liquid biopsy approaches will be important for advancing the clinical application of sarcoma-derived EVs and improving disease monitoring and patient management.

  • Open Access

    Enhanced formation of tertiary lymphoid structures shapes the anti-tumor microenvironment in gastrointestinal stromal tumors after imatinib targeted therapy

    by Ping Tao, Jiongyuan Wang, Peidang Fan, Wenshuai Liu, Weiqi Lu, Yujie Hu, Qun Lu, Lijie Ma, Hanxing Tong, Yong Zhang

    Rationale: Tertiary lymphoid structures (TLSs) play a key role in the adaptive immune response within the local tumor immune microenvironment (TIME) and can predict the clinical outcome of several solid tumors. However, the clinical relevance of TLSs and their formation mechanism in gastrointestinal stromal tumors (GISTs) remain unclear. Methods: Integration analysis was performed on a single-cell RNA sequencing (scRNA-seq) cohort (n = 8), a public transcriptome cohort (n = 65), a public scRNA-seq cohort (n = 7), a tissue cohort (n = 197) and a serum cohort (n = 169) to decode the characteristics of the immunological microenvironment of GIST. The multiplex immunohistochemistry (mIHC) staining, in vitro cell culture, chemotaxis assays and antibody-dependent cellular phagocytosis (ADCP) experiments were used to validate the results of the bioinformatics analysis. Results: Preoperative imatinib targeted therapy significantly enhanced TLS formation in GIST tissues, predicting improved therapeutic efficacy and favorable prognosis. Mechanistically, imatinib remodeled the local microenvironment via tumour-associated macrophages, recruiting B cells via the CXCR4-CXCL12 axis to drive TLS development. Functionally, TLS dominated germinal centre (GC) B-cell differentiation and the formation of IgG + plasma cells (PCs), which preferentially enhanced the adaptive immune response through the ADCP effect. From a clinical perspective, we identified three distinct GIST immune classes (GICs A-C). GIC-A tumors featured abundant CD20 + B cells and TLS, as well as a favorable prognosis. They were accompanied by enhanced antigen presentation, accumulation of IgG + PCs, increased immunosuppressive properties and a high frequency of KIT exon 11 mutations. These mutations potentially serve as a predictive biomarker for future targeted and immunotherapies. Furthermore, patients with high serum IgG levels experienced significant therapeutic benefits. Conclusions: Our data show that local adaptive immunity dominated by TLS is a key factor in the efficacy of targeted therapy, and suggest that inducing IgG could be a feasible strategy for improving the prognosis of patients with GIST.


  • Dual-locked SO2/nanozyme delivery nanoplatform for programmed synergistic gas/chemodynamic anticancer therapy

    by Tianyu Zhong, Tao Zhu, Ya Li, Shuqi Wang, Quan Jiang, Yong Zhang, Yongsheng Li, Yuanyuan Cao


  • Open Access

    Genetically engineered GSDME vesicle coated nanoparticle for immune activating and pyroptosis inducing synergetic therapy of fibrosarcoma

    by Fenglin Miao, Zhao Wang, Qing Wang, Changsheng Zhou, Xiao Zhou, Jialiang Zheng, Yuan Ma, Zhenhang Lin, Yilai Gao, Ting Wu, et al.


  • Ubiquilin-4 induces immune escape in gastric cancer by activating the notch signaling pathway

    by Quan Jiang, Hao Chen, Shixin Zhou, Tao Zhu, Wenshuai Liu, Hao Wu, Yong Zhang, Fenglin Liu, Yihong Sun

    Purpose We aimed to investigate the role of ubiquilin-4 in predicting the immunotherapy response in gastric cancer. Methods Retrospective RNA-sequencing and immunohistochemical analysis were performed for patients with gastric cancer who received programmed death-1 blockade therapy after recurrence. Multiplex immunohistochemistry identified immune cell types in gastric cancer tissues. We used immunocompetent 615 mice and immunodeficient nude mice to perform tumorigenic experiments. Results Ubiquilin-4 expression was significantly higher in responders (p < 0.05, false discovery rate > 2.5) and showed slight superiority over programmed death ligand 1 in predicting programmed death-1 inhibitor therapy response (area under the curve: 87.08 vs. 72.50). Ubiquilin-4-high patients exhibited increased CD4+ and CD8+ T cells, T follicular helper cells, monocytes, and macrophages. Ubiquilin-4-overexpressed mouse forestomach carcinoma cells showed significantly enhanced growth in immunocompetent mice but not in immunodeficient mice. Upregulation or downregulation of ubiquilin-4 synergistically affected programmed death ligand 1 at the protein and messenger RNA levels. Functional enrichment analysis revealed significant enrichment of the Notch, JAK-STAT, and WNT signaling pathways in ubiquilin-4-high gastric cancers. Ubiquilin-4 promoted Numb degaration, activating the Notch signaling pathway and upregulating programmed death ligand 1. Conclusions Ubiquilin-4 may contribute to immune escape in gastric cancer by upregulating programmed death ligand 1 expression in tumor cells through Notch signaling activation. Thus, ubiquilin-4 could serve as a predictive marker for programmed death ligand 1 inhibitor therapy response in gastric cancer.


  • Open Access

    Single-Cell RNA-Sequencing Reveals Peripheral T Helper Cells Promoting the Development of IgG4-Related Disease by Enhancing B Cell Activation and Differentiation

    by Zongfei Ji, Weiqi Lu, Sifan Wu, Yong Zhang, Dan Meng, Xiao Zhang, Xiaojuan Dai, Huiyong Chen, Lili Ma, Ying Sun, et al.

    Abnormal B cell differentiation plays a critical role in IgG4-related disease (IgG4-RD), but the underlying mechanism remains largely unknown. We investigated the cell landscape from three IgG4-RD retroperitoneal tissues and three control tissues using single-cell RNA-sequencing. Critical cell type or markers were further validated in the peripheral blood from the patients with IgG4-RD and healthy controls via flow cytometry as well as in the IgG4-RD and control tissue via immunofluorescence staining. The increases in B cells, plasma cells, and CD4+ T cells were found in IgG4-RD retroperitoneal tissue. Importantly, among CD4+ T cells, an increase in CD4+CXCR5−PD1hi peripheral T helper (Tph) cells with a high expression of IL-21 and TIGIT was discovered in IgG4-RD tissue, which was further validated in peripheral blood of the patients with IgG4-RD. The Tph cell and TIGIT+ Tph cell proportion were remarkably higher in active IgG4-RD patients and correlated with disease activity. Moreover, TIGIT+CD4+ cells were able to promote B cell differentiation via IL-21. Our study revealed that Tph cells are increased in IgG4-RD and probably play critical roles in B cell differentiation through TIGIT-IL-21 axis. Peripheral Tph cell and TIGIT+Tph cell are potential markers for IgG4-RD disease activity.


  • Open Access

    Insight of a lipid metabolism prognostic model to identify immune landscape and potential target for retroperitoneal liposarcoma

    by Zhenyu Wang, Ping Tao, Peidang Fan, Jiongyuan Wang, Tao Rong, Yingyong Hou, Yuhong Zhou, Weiqi Lu, Liang Hong, Lijie Ma, et al.

    Introduction: The exploration of lipid metabolism dysregulation may provide novel perspectives for retroperitoneal liposarcoma (RPLS). In our study, we aimed to investigate potential targets and facilitate further understanding of immune landscape in RPLS, through lipid metabolism-associated genes (LMAGs) based prognostic model.Methods: Gene expression profiles and corresponding clinical information of 234 cases were enrolled from two public databases and the largest retroperitoneal tumor research center of East China, including cohort-TCGA (n=58), cohort-GSE30929 (n=92), cohort-FD (n=50), cohort-scRNA-seq (n=4) and cohort-validation (n=30). Consensus clustering analysis was performed to identify lipid metabolism-associated molecular subtypes (LMSs). A prognostic risk model containing 13 LMAGs was established using LASSO algorithm and multivariate Cox analysis in cohort-TCGA. ESTIMATE, CIBERSORT, XCELL and MCP analyses were performed to visualize the immune landscape. WGCNA was used to identify three hub genes among the 13 model LMAGs, and preliminarily validated in both cohort-GSE30929 and cohort-FD. Moreover, TIMER was used to visualize the correlation between antigen-presenting cells and potential targets. Finally, single-cell RNA-sequencing (scRNA-seq) analysis of four RPLS and multiplexed immunohistochemistry (mIHC) were performed in cohort-validation to validate the discoveries of bioinformatics analysis.Results: LMS1 and LMS2 were characterized as immune-infiltrated and -excluded tumors, with significant differences in molecular features and clinical prognosis, respectively. Elongation of very long chain fatty acids protein 2 (ELOVL2), the enzyme that catalyzed the elongation of long chain fatty acids, involved in the maintenance of lipid metabolism and cellular homeostasis in normal cells, was identified and negatively correlated with antigen-presenting cells and identified as a potential target in RPLS. Furthermore, ELOVL2 was enriched in LMS2 with significantly lower immunoscore and unfavorable prognosis. Finally, a high-resolution dissection through scRNA-seq was performed in four RPLS, revealing the entire tumor ecosystem and validated previous findings.Discussion: The LMS subgroups and risk model based on LMAGs proposed in our study were both promising prognostic classifications for RPLS. ELOVL2 is a potential target linking lipid metabolism to immune regulations against RPLS, specifically for patients with LMS2 tumors.


  • Open Access

    Lipidomics and Transcriptomics Differ Liposarcoma Differentiation Characteristics That Can Be Altered by Pentose Phosphate Pathway Intervention

    by Zhengqing Song, Shuaikang Wang, Lili Lu, Jingshen Xu, Qiwen Zhou, Weiqi Lu, Hanxing Tong, Yong Zhang, Wenshuai Liu, Zhiming Wang, et al.

    Liposarcoma (LPS) is a rare and heterogeneous malignancy of adipocytic origin. Well-differentiated liposarcoma (WDLPS) and dedifferentiated liposarcoma (DDLPS) are two of the most common subtypes, showing similar genetic characterizations but distinct biological behaviors and clinical prognosis. Compared to WDLPS, DDLPS is more aggressive and has the potential of metastasis, as the malignant adipocytic tumor’s metabolic changes may have taken place during the tumorigenesis of LPSs. Therefore, to investigate the lipid alterations between the two subtypes, high-resolution liquid chromatography tandem mass spectrometry (LC-MS/MS) based untargeted lipidomic analysis was performed onto LPS tissues from 6 WDLPS and 7 DDLPS patients. The lipidomic analysis showed the upregulated phosphatidylcholines and phosphoethanolamines in DDLPS, and the upregulated triglycerides and diglycerides in WDLPS, which might be due to the uncompleted adipocytic dedifferentiation leading to such tumorigenesis. Such a finding was also confirmed by the similarity comparison of two LPS subtypes to the transcriptome of stromal vascular fraction at different differentiation stages. Transcriptomic analysis also demonstrated that metabolic pathways including the pentose phosphate pathway (PPP) were upregulated in WDLPS compared to DDLPS. Therefore, the cell line LPS853 was treated with the PPP inhibitor 6-aminonicotinamide ex vivo and the proliferation and invasion of LPS853 was significantly promoted by PPP inhibition, suggesting the potential role of PPP in the development and differentiation of LPS. In conclusion, this study described the altered lipid profiles of WDLPS and DDLPS for the first time, revealing the different differentiation stages of the two subtypes and providing a potential metabolic target for LPS treatment.